Royalty Pharma (RPRX) Non-Current Assets (2019 - 2026)

Royalty Pharma has disclosed Non-Current Assets across 8 years of filings, most recently posting $18.1 billion for Q2 2026.

• In Q2 2026, Non-Current Assets rose 7.45% year-over-year to $18.1 billion; the TTM figure through Jun 2026 stood at $72.0 billion (up 10.42% YoY), while the FY2025 annual figure was $18.1 billion, up 10.18% from the prior year.
• Non-Current Assets came in at $18.1 billion for Q2 2026 at Royalty Pharma, down from $18.4 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $18.4 billion in Q1 2026 to a low of $14.1 billion in Q3 2023.
• Average Non-Current Assets over 5 years is $15.7 billion, with a median of $15.2 billion recorded in 2022.
• Year-over-year, Non-Current Assets dropped 7.85% in 2023 and rose 16.65% in 2026.
• Over 5 years, Non-Current Assets stood at $14.3 billion in 2022, then advanced by 5.96% to $15.1 billion in 2023, then advanced by 8.69% to $16.4 billion in 2024, then gained by 10.18% to $18.1 billion in 2025, then slipped by 0.21% to $18.1 billion in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $18.1 billion in Q2 2026, $18.4 billion in Q1 2026, and $18.1 billion in Q4 2025.